NCT02943213 - Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Anti-PsychoticManagement of Manifestations of Psychotic DisordersTreatment of SchizophreniaControl Nausea and VomitingRelief of Restlessness and Apprehension Before SurgeryAcute Intermittent PorphyriaAdjunct in the Treatment of TetanusControl Manifestations of the Manic Type of Mani-depressive IllnessRelief of Intractable Hiccups

Interventions

DRUG

Chlorpromazine Hydrochloride

Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.

Trial Locations (1)

9300

Farmovs Parexel, Bloemfontein